These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 9610868

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. DNA damage in peripheral blood mononuclear cells correlates with response to biochemotherapy in melanoma.
    Buzaid AC, Ali-Osman F, Akande N, Grimm EA, Lee JJ, Bedikian A, Eton O, Papadopoulos N, Plager C, Legha SS, Benjamin RS.
    Melanoma Res; 1998 Apr; 8(2):145-8. PubMed ID: 9610867
    [Abstract] [Full Text] [Related]

  • 3. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS, Ring S, Bedikian A, Plager C, Eton O, Buzaid AC, Papadopoulos N.
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [Abstract] [Full Text] [Related]

  • 4. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy.
    Grimm EA, Smid CM, Lee JJ, Tseng CH, Eton O, Buzaid AC.
    Clin Cancer Res; 2000 Oct; 6(10):3895-903. PubMed ID: 11051235
    [Abstract] [Full Text] [Related]

  • 5. Mechanism of the anti-tumour effect of biochemotherapy in melanoma: preliminary results.
    Buzaid AC, Grimm EA, Ali-Osman F, Ring S, Eton O, Papadopoulos NE, Bedikian A, Plager C, Legha SS, Benjamin R.
    Melanoma Res; 1994 Oct; 4(5):327-30. PubMed ID: 7858418
    [Abstract] [Full Text] [Related]

  • 6. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE.
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases.
    Buzaid AC, Colome M, Bedikian A, Eton O, Legha SS, Papadopoulos N, Plager C, Ross M, Lee JE, Mansfield P, Rice J, Ring S, Lee JJ, Strom E, Benjamin R.
    Melanoma Res; 1998 Dec; 8(6):549-56. PubMed ID: 9918417
    [Abstract] [Full Text] [Related]

  • 8. Clinical results using biochemotherapy as a standard of care in advanced melanoma.
    Chapman PB, Panageas KS, Williams L, Wolchok JD, Livingston PO, Quinn C, Hwu WJ.
    Melanoma Res; 2002 Aug; 12(4):381-7. PubMed ID: 12170188
    [Abstract] [Full Text] [Related]

  • 9. Development and results of biochemotherapy in metastatic melanoma: the University of Texas M.D. Anderson Cancer Center experience.
    Legha SS, Ring S, Eton O, Bedikian A, Plager C, Papadopoulos N.
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S9-15. PubMed ID: 9457387
    [Abstract] [Full Text] [Related]

  • 10. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
    Eton O, Legha SS, Bedikian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS.
    J Clin Oncol; 2002 Apr 15; 20(8):2045-52. PubMed ID: 11956264
    [Abstract] [Full Text] [Related]

  • 11. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
    Buzaid AC, Legha SS.
    Semin Oncol; 1994 Dec 15; 21(6 Suppl 14):23-8. PubMed ID: 7992096
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.
    J Clin Oncol; 2009 Dec 20; 27(36):6207-12. PubMed ID: 19917850
    [Abstract] [Full Text] [Related]

  • 15. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS, Ring S, Eton O, Bedikian A, Buzaid AC, Plager C, Papadopoulos N.
    J Clin Oncol; 1998 May 20; 16(5):1752-9. PubMed ID: 9586888
    [Abstract] [Full Text] [Related]

  • 16. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.
    Cancer; 2002 Jan 15; 94(2):470-6. PubMed ID: 11900232
    [Abstract] [Full Text] [Related]

  • 17. Biochemotherapy in patients with advanced vulvovaginal mucosal melanoma.
    Harting MS, Kim KB.
    Melanoma Res; 2004 Dec 15; 14(6):517-20. PubMed ID: 15577323
    [Abstract] [Full Text] [Related]

  • 18. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J.
    Clin Cancer Res; 2005 Feb 01; 11(3):1237-46. PubMed ID: 15709194
    [Abstract] [Full Text] [Related]

  • 19. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P, Iannucci A, Becker M, Allen J, O'Driscoll M, McDowell K, Williams P, Rosse P, Murphy J, Gonzalez R.
    Melanoma Res; 2000 Apr 01; 10(2):171-9. PubMed ID: 10803718
    [Abstract] [Full Text] [Related]

  • 20. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.
    Flaherty LE, Othus M, Atkins MB, Tuthill RJ, Thompson JA, Vetto JT, Haluska FG, Pappo AS, Sosman JA, Redman BG, Moon J, Ribas A, Kirkwood JM, Sondak VK.
    J Clin Oncol; 2014 Nov 20; 32(33):3771-8. PubMed ID: 25332243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.